Undp Guinea Bissau Pharmaceutical Import Profile — Guinea Bissau (DGFT 2022–2026)

Name: Undp Guinea Bissau Pharmaceutical Import Records from India — 2 Products, $200.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Undp Guinea Bissau — Pharmaceutical Importer Profile (2026) | 2 Products, $200.0K Trade | TransData Nexus

Undp Guinea Bissau

Pharmaceutical Importer · Guinea Bissau · Antimalarial & Antiparasitic Focus · $200.0K Total Trade · DGFT Verified

Undp Guinea Bissau is a pharmaceutical importer based in Guinea Bissau with a total trade value of $200.0K across 2 products in 1 therapeutic categories. Based on 4 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Undp Guinea Bissau sources from 2 verified Indian suppliers, with Macleods Pharmaceuticals Limited accounting for 95.4% of imports.

Undp Guinea Bissau — Import Portfolio & Supplier Network

Undp Guinea Bissau import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Undp Guinea Bissau?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$100.0K	2	95.4%
Cipla Limited	$4.8K	4	4.6%

Undp Guinea Bissau sources from 2 verified Indian suppliers across .

What Formulations Does Undp Guinea Bissau Import?

Formulation	Value	Ships
Amodiaquine dispersible tablets 76 5MG sulfadoxine pyrimethamine dispersible tablets 250MG 12 5MG 50x4	$50.0K	1
Amodiaquine dispersible tablets 153MG sulfadoxine pyrimethamine dispersible tablets 500MG 25MG 50x4	$50.0K	1
Lumartem dt artemether lumefantrine dispersible tablets 20 120MG 405 packx30x12 s 145800	$4.3K	1
Lumartem dt artemether lumefantrine dispersible tablets 20 120MG 45 packx30x12 s 16200	$478	1
I we undertake to abide by provisions of foreign exchange management act 1999 as amended from time to time	$0	1
Lut arn no ad230325024901i dt 27 03 2025 valid up to 31 03	$0	1

Undp Guinea Bissau imports 6 distinct pharmaceutical formulations. Showing top 6 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pyrimethamine	Antimalarial & Antiparasitic	$100.0K	2	0.2%	11
2	Sulfadoxine	Antimalarial & Antiparasitic	$100.0K	2	0.2%	10

Undp Guinea Bissau imports 2 pharmaceutical products across 1 categories into Guinea Bissau totaling $200.0K.

Undp Guinea Bissau — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Undp Guinea Bissau is the United Nations Development Programme's (UNDP) operational arm in Guinea-Bissau, focusing on sustainable development initiatives across various sectors, including health. As a governmental entity, it is not a traditional pharmaceutical wholesaler or distributor but plays a pivotal role in the procurement and distribution of essential medicines and health commodities within the country. Headquartered in Bissau, Guinea-Bissau, Undp Guinea Bissau operates under the auspices of the UNDP, which is headquartered in New York, USA. Its primary function in the pharmaceutical supply chain is to ensure the availability and equitable distribution of life-saving medicines, particularly in underserved and remote areas. This involves sourcing, importing, and managing the logistics of pharmaceutical products to meet the nation's health needs.

2Distribution Network

Undp Guinea Bissau's distribution network is designed to ensure the efficient delivery of medical supplies across the country. The organization operates a central warehouse located in Bissau, which serves as the main hub for storing and managing pharmaceutical products. This facility is equipped with modern logistics capabilities, including temperature-controlled storage areas to maintain the efficacy of sensitive medications. From the central warehouse, medicines are distributed to regional health centers and local clinics, ensuring that essential health commodities reach even the most remote communities. The distribution network is supported by partnerships with international organizations and local authorities, facilitating the smooth flow of medical supplies throughout Guinea-Bissau.

3Industry Role

In Guinea-Bissau's pharmaceutical supply chain, Undp Guinea Bissau functions as a central procurement and distribution entity rather than a traditional wholesaler or parallel importer. Its role is to source and import essential medicines, ensuring their availability and proper distribution to meet the country's health needs. This involves coordinating with international suppliers, managing logistics, and overseeing the storage and distribution processes to maintain the quality and integrity of pharmaceutical products. By fulfilling this role, Undp Guinea Bissau contributes significantly to the strengthening of the national health system and the improvement of public health outcomes.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Undp Guinea Bissau

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Undp Guinea Bissau's sourcing strategy exhibits a high degree of concentration, with a total import value of $200,000 USD from India across four shipments, all comprising two products: Pyrimethamine and Sulfadoxine. Both products are antimalarial agents, indicating a targeted approach to addressing malaria, a significant health concern in Guinea-Bissau. The exclusive reliance on two products from a single supplier, MACLEODS PHARMACEUTICALS LIMITED, which accounts for 95.4% of the total import value, suggests a strategic choice to ensure a consistent and reliable supply of these critical medications. However, this concentration also presents potential risks, such as supply chain disruptions or changes in supplier conditions. The presence of a secondary supplier, CIPLA LIMITED, providing the remaining 4.6% of the imports, offers a degree of diversification, but the overall sourcing strategy remains highly concentrated.

2Supply Chain Resilience

The resilience of Undp Guinea Bissau's supply chain is closely tied to its sourcing strategy. The heavy reliance on a single supplier for the majority of imports could pose challenges in the event of supply disruptions or changes in supplier conditions. While the inclusion of a secondary supplier provides some level of diversification, it may not be sufficient to fully mitigate potential risks. The organization's focus on antimalarial agents aligns with national health priorities, but the limited product range may restrict flexibility in addressing other health needs. To enhance supply chain resilience, it would be prudent for Undp Guinea Bissau to consider diversifying its supplier base and expanding the range of imported pharmaceutical products, thereby reducing dependency on a single source and improving the overall robustness of the supply chain.

Importing Pharmaceuticals into Guinea Bissau — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Guinea Bissau

1Regulatory Authority & Framework

The pharmaceutical regulatory framework in Guinea-Bissau is overseen by the Regulatory Authority for Pharmacy, Laboratory, and Medicines (ARFAME), which is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products within the country. In September 2025, Guinea-Bissau implemented a national pharmaceutical traceability system, known as the AVG Pharmaceutical Traceability Hub, to monitor and authenticate medicines throughout the supply chain. This system mandates the use of unique identifiers, including the Global Trade Item Number (GTIN), batch number, expiration date, and serial number, to enhance transparency and combat counterfeit medicines. The regulation applies to all pharmaceutical products intended for human use, with certain exemptions, and requires all supply chain participants to record and communicate traceability data to the national system. (softgroup.eu)

2Import Licensing & GMP

Import licensing requirements in Guinea-Bissau stipulate that all pharmaceutical products must be registered with the Ministry of Health before being imported into the country. This process involves submitting documentation on the product's composition, labeling, and efficacy. Guinea-Bissau recognizes international standards, such as those from the European Union and Portugal, for Good Manufacturing Practice (GMP) certification. Pharmaceutical products imported into Guinea-Bissau must comply with these recognized GMP standards to ensure quality and safety. Additionally, importers must provide standard documents, including commercial invoices, certificates of origin, and, where applicable, Certificates of Conformity or sanitary/phytosanitary approvals.

Undp Guinea Bissau — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Undp Guinea Bissau's product strategy focuses on importing antimalarial agents, specifically Pyrimethamine and Sulfadoxine, to address the high prevalence of malaria in the country. This targeted approach aligns with national health priorities and ensures a consistent supply of essential medications for malaria treatment. The decision to import these specific products is driven by the urgent need to combat malaria, which remains a significant health challenge in Guinea-Bissau. By focusing on these therapeutic areas, Undp Guinea Bissau aims to improve health outcomes and reduce the burden of malaria on the population.

2Sourcing Profile

Undp Guinea Bissau's sourcing strategy is centered on importing generic antimalarial medications from India, with a particular emphasis on Pyrimethamine and Sulfadoxine. This approach leverages India's established pharmaceutical manufacturing capabilities and cost-effectiveness, ensuring the availability of essential medicines at affordable prices. The focus on generic formulations allows Undp Guinea Bissau to procure high-quality medications without the financial burden associated with branded products. By sourcing from India, Undp Guinea Bissau can maintain a reliable supply chain and meet the country's health needs effectively.

3Market Positioning

Seller's Guide — How to Become a Supplier to Undp Guinea Bissau

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Undp Guinea Bissau, particularly by offering a broader range of pharmaceutical products that align with Guinea-Bissau's health priorities. While the current sourcing pattern is concentrated on antimalarial agents, expanding the product portfolio to include other essential medicines

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Undp Guinea Bissau

What products does Undp Guinea Bissau import from India?

Undp Guinea Bissau imports 2 pharmaceutical products across 1 categories. Top imports: Pyrimethamine ($100.0K), Sulfadoxine ($100.0K).

Who supplies pharmaceuticals to Undp Guinea Bissau from India?

Undp Guinea Bissau sources from 2 verified Indian suppliers. The primary supplier is Macleods Pharmaceuticals Limited (95.4% of imports, $100.0K).

What is Undp Guinea Bissau's total pharmaceutical import value?

Undp Guinea Bissau's total pharmaceutical import value from India is $200.0K, based on 4 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Undp Guinea Bissau focus on?

Undp Guinea Bissau imports across 1 categories. The largest: Antimalarial & Antiparasitic (100.0%).

Get Full Undp Guinea Bissau Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.